

**Heme oxygenase-1 expression is
increased to protect podocyte
apoptosis under diabetic conditions**

Sang Choel Lee

Department of Medicine

The Graduate School, Yonsei University

**Heme oxygenase-1 expression is
increased to protect podocyte
apoptosis under diabetic conditions**

Directed by Professor Shin-Wook Kang

Doctoral Dissertation submitted to the Department of
Medicine, the Graduate School of Yonsei University
in partial fulfillment of the requirements for the degree
of Doctor of Philosophy

Sang Choel Lee

June 2008

**This certifies that the Doctoral
Dissertation of Sang Choel Lee is
approved.**

Thesis Supervisor : Shin-Wook Kang

(Hyeon Joo Jeong: Thesis Committee Member#1)

(Soon-Jung Park: Thesis Committee Member#2)

(Koon Ho Rha: Thesis Committee Member#3)

(Soo Young Yoon: Thesis Committee Member#4);

The Graduate School
Yonsei University

June 2008

ACKNOWLEDGEMENTS

I am deeply indebted to my supervisor Prof. Shin-Wook Kang who has given me a confidence and courage to write this thesis. His solid advices, logical way of thinking and brilliant academic supports enabled me, who had not done much research work with laboratory technique, to finish this work, and it would influence in my whole life.

I also would like to appreciate Prof. Hyeon Joo Jeong, Prof. Soon-Jung Park, Prof. Koon Ho Rha, and Prof. Soo Young Yoon for their kind guidance and support. I would like to give my warm and sincere thanks to Jin Ji Li, Dong Sub Jung, Seung Jae Kwak, Je Hyun Park, Sun Ha Lee, and Seung Hye Kim who gave all their helps and supports. Especially I would appreciate Seung Hyeok Han, my lovely colleague and friend who was great help from the beginning to the end of writing the thesis.

I owe my loving thanks to my wife Sun Hee Park, my son Chang Whi Lee and my daughter Seung Eun Lee who always provide a great pleasure to me. Without their encouragement and understanding it would have been impossible for me to finish this work. My special gratitude is due to my parents, parents-in-law, my brother, my sisters for their loving support and prayer.

“In his heart a man plans his course, but the LORD determines his steps. Proverb 16:9.” Really I planned my way, but God led me to be on the right road. Finally and most importantly, I would like to give thanks to God, for it is under his grace that I can finish this thesis.

<TABLE OF CONTENTS>

ABSTRACT	1
I. INTRODUCTION	5
II. MATERIALS AND METHODS	9
1. Animals	9
2. Glomerular isolation	9
3. Podocytes culture	10
4. Total RNA isolation	11
5. Reverse transcription	12
6. Real-time PCR	12
7. Western blot analysis	14
8. Immunohistochemistry	15
9. Immunofluorescence	16
10. TUNEL assay and Hoechst 33342 staining	17
11. Statistical analysis	18
III. RESULTS	19
1. Animal studies	19
A. Clinical data	19
B. Glomerular expression of HO-1 mRNA and protein	20
C. Immunohistochemical staining for glomerular HO-1	23

D. Bax, Bcl-2, and active fragments of caspase-3 protein expression	25
E. TUNEL assay and double immunofluorescence staining	27
F. Podocyte numbers	30
2. Cultured podocytes studies	31
A. HO-1 protein expression	31
B. Bax, Bcl-2 and active fragments of caspase-3 expression	34
C. Hoechst 33342 staining	36
IV. DISCUSSION	37
V. CONCLUSION	46
REFERENCES	49
Abstract (in Korean)	60

LIST OF FIGURES

Figure 1. Glomerular HO-1 mRNA expression assessed by real-time PCR in C, C+ZnPP, DM, and DM+ZnPP rats--	21
Figure 2. A representative Western blot of glomerular HO-1 in C, C+ZnPP, DM, and DM+ZnPP rats -----	22
Figure 3. Immunohistochemical staining for HO-1 in C, C+ZnPP, DM, and DM+ZnPP rats -----	24
Figure 4. A representative Western blot of Bax, Bcl-2, and active fragments of caspase-3 protein expression in C, C+ZnPP, DM, and DM+ZnPP glomeruli -----	26
Figure 5. Apoptosis assessed by TUNEL assay in C, C+ZnPP, DM and DM+ZnPP rats -----	28
Figure 6. Double immunofluorescence staining for active fragments of caspase-3 and synaptopodin -----	29
Figure 7. Podocyte numbers in C, C+ZnPP, DM, and DM+ZnPP rats-----	30

Figure 8. A representative Western blot of HO-1 in cultured podocytes treated with three different concentrations of HO-1 siRNA ----- 32

Figure 9. A representative Western blot of HO-1 in cultured podocytes exposed to NG, NG+M, and HG medium ----- 33

Figure 10. A representative Western blot of Bax, Bcl-2, and active fragments of caspase-3 in cultured podocytes ----- 35

Figure 11. Apoptosis assessed by Hoechst 33342 staining-----
-----36

LIST OF TABLES

Table 1. Animal data ----- 19

ABSTRACT

Heme oxygenase-1 expression is increased to protect podocyte apoptosis under diabetic conditions

Sang Choel Lee

Department of Medicine

The Graduate School, Yonsei University

(Directed by Professor Shin-Wook Kang)

Background: Diabetic nephropathy, the leading cause of end-stage renal disease in many countries, is clinically characterized by proteinuria. Recent studies have shown that podocyte injury plays an important role in the pathogenesis of various proteinuric glomerular diseases, including diabetic nephropathy. The number of podocytes is decreased in diabetic glomeruli and reactive oxygen species-mediated apoptosis is known to be involved in the process of podocyte loss under diabetic conditions. Heme oxygenase-1 (HO-1), a microsomal enzyme, has been regarded as an anti-oxidant and to be

upregulated to alleviate the deleterious consequences of oxidant injury. Previous studies have demonstrated that HO-1 expression is increased in experimental diabetic glomeruli, but the functional significance of this increase has not yet been explored. In this study, to elucidate the role of HO-1 in podocyte apoptosis under diabetic conditions, I investigated not only the expression of HO-1 but also podocyte apoptosis in experimental diabetic glomeruli and in high glucose-stimulated cell before and after inhibition of HO activity.

Methods: In vivo, 32 Sprague-Dawley rats were injected either with diluent (n=16, C) or with streptozotocin intraperitoneally (IP) (n=16, DM), and 8 rats from each group were treated with IP Zinc protoporphyrin (ZnPP, 50 $\mu\text{mol/kg/day}$), an HO-1 inhibitor, for 6 weeks. In vitro, immortalized mouse podocytes were cultured in media containing 5.6 mM glucose (NG), NG+24.4 mM mannitol (NG+M), or 30 mM glucose (HG) with or without HO-1 siRNA. Real-time PCR for HO-1 mRNA expression and Western blotting for HO-1, Bax, Bcl-2, and active fragments of caspase-3 protein expression were performed with sieved glomeruli and cell lysates. In addition, TUNEL assay and immunofluorescence (IF) staining for active fragments of caspase-3 were conducted with renal tissue and Hoechst 33342 staining with cultured podocytes.

Results: Urinary albumin excretion was significantly higher in DM (1.18±0.11 mg/day) compared to C rats (0.32±0.04 mg/day) ($p<0.05$), and was further increased in DM rats by ZnPP (1.59±0.19 mg/day) ($p<0.05$). HO-1 mRNA and protein expression were increased in diabetic glomeruli and in HG-stimulated podocytes, and these increases were inhibited by ZnPP and HO-1 siRNA, respectively. The ratios of Bax/Bcl-2 protein expression were significantly higher in diabetic glomeruli and in podocytes exposed to HG, which were further increased by ZnPP and HO-1 siRNA, respectively. Western blotting with active fragments of caspase-3 showed a similar pattern to the ratios of Bax/Bcl-2 protein expression. TUNEL positive-stained nuclei were also significantly increased in DM (1.3±0.2) compared to C glomeruli (0.4±0.1) ($p<0.05$), and were further increased in DM glomeruli by ZnPP (2.2±0.3) ($p<0.05$). In addition, double IF staining with active fragments of caspase-3 and synaptopodin revealed that active fragments of caspase-3 expression was most prominent in podocytes of DM+ZnPP rats. Apoptotic cells assessed by Hoechst 33342 staining were also significantly increased in HG-stimulated podocytes compared to NG cells, which were further increased in HG+siRNA group.

Conclusion: This study suggests that HO-1 expression is increased in experimental diabetic glomeruli and in HG-stimulated podocytes, and the

increase in HO-1 expression plays a protective role against podocyte apoptosis under diabetic conditions.

Key words: heme oxygenase-1, diabetic nephropathy, podocyte, high glucose, apoptosis

Heme oxygenase-1 expression is increased to protect podocyte apoptosis under diabetic conditions

Sang Choel Lee

*Department of Medicine
The Graduate School, Yonsei University*

(Directed by Professor Shin-Wook Kang)

I. INTRODUCTION

Diabetic nephropathy, the leading cause of end-stage renal disease in many countries, is clinically characterized by proteinuria¹. The underlying pathologic change responsible for proteinuria in various glomerular diseases is the loss of size-selective and/or charge-selective properties of the glomerular filtration barrier². The glomerular filtration barrier is comprised of three layers: a fenestrated endothelial layer, a glomerular basement membrane (GBM), and podocyte foot processes connected by a slit diaphragm³. Recent studies have shown that podocyte injury plays an important role in the pathogenesis of various proteinuric glomerular diseases, including diabetic nephropathy⁴⁻⁶.

The number of podocytes is decreased in the glomeruli of diabetic patients and animal models of diabetes, and apoptosis is known to be involved in the process of podocyte loss under diabetic conditions⁷⁻⁹. Previous studies have demonstrated that high glucose *per se* and transforming growth factor (TGF)- β 1, two major mediators in the development and progression of diabetic nephropathy, increase reactive oxygen species (ROS) production and induce apoptosis in cultured podocytes¹⁰⁻¹². Moreover, podocyte apoptosis under these conditions is prevented by the administration of anti-oxidants, suggesting that oxidative stress with increased ROS is responsible for apoptosis of podocytes under diabetic conditions^{12, 13}.

Heme oxygenase (HO) is a microsomal rate-limiting enzyme involved in the degradation of heme to biliverdin, which is rapidly converted to bilirubin by biliverdin reductase¹⁴⁻¹⁷. During this step, iron is released from the heme ring and carbon monoxide (CO) is generated. To date, three distinct isoforms of HO have been identified: HO-1, an inducible form; HO-2, a constitutive form; and HO-3, probably a pseudogene¹⁸. Among these, HO-1 is the most extensively studied HO isoenzyme and is known to be upregulated in the kidney under various conditions characterized by oxidative stress^{19, 20}, including toxic nephropathy^{21, 22}, ischemia-reperfusion injury²³, contrast

nephropathy²⁴, acute transplant rejection²⁵, and diabetic nephropathy²⁶. Oxidants generating molecules such as angiotensin II (AII)²⁷, heme²⁸, proinflammatory cytokine²⁹, and TGF- β 1³⁰ are also reported to induce HO-1. In addition, pharmacological inhibition of HO-1 activity or deletion of HO-1 gene worsened renal injury induced by toxic substances³¹ and ischemia-reperfusion³², while prior induction of HO-1 protected against renal injury. Based on these findings, HO-1 has been regarded as an anti-oxidant and to be upregulated to alleviate the deleterious consequences of oxidant injury.

Recently, experimental and clinical evidences indicate that excessive oxidative stress may contribute to the initiation and development of diabetic nephropathy. Furthermore, the attenuation of experimental diabetic nephropathy by dietary anti-oxidant supplementation with vitamin E²⁶, taurine³³, or lipoic acid^{13, 34} also supports the role of oxidative stress in the pathogenesis of diabetic nephropathy. Based on these findings, an increase in HO-1 expression has been expected and been demonstrated in experimental diabetic glomeruli, mainly in mesangial cells and podocytes³⁵, but the functional significance of this increase has not yet been explored. In this study, to elucidate the role of HO-1 in podocyte apoptosis under diabetic conditions, which oxidative stress is known to mediate, I investigated not only the

expression of HO-1 but also podocyte apoptosis in experimental diabetic glomeruli and in high glucose-stimulated cells before and after inhibition of HO activity.

II. MATERIALS AND METHODS

1. Animals

All animal studies were conducted under an approved protocol. Sprague-Dawley rats weighing 250-280 g were injected either with diluent [n=16, Control (C)] or with 65 mg/kg streptozotocin (STZ) intraperitoneally (IP) [n=16, Diabetes (DM)]. Eight rats from each group were treated with IP Zinc protoporphyrin (ZnPP) (50 $\mu\text{mol/kg/day}$) (Sigma-Aldrich Corp., Saint Louis, MO, USA) (C+ZnPP, DM+ZnPP) for 6 weeks. Rats were housed in a temperature-controlled room and were given free access to water and standard laboratory chow during the 6-weeks study period.

Body weights were checked after 6 weeks, and kidney weights were measured at the time of sacrifice. Serum glucose and 24-hour urinary albumin were measured weekly and at the time of sacrifice, respectively. Blood glucose was measured by glucometer and 24-hour urinary albumin excretion (UAE) was determined by ELISA (Nephurat II, Exocell, Inc., Philadelphia, PA, USA).

2. Glomerular isolation

Glomeruli were isolated by sieving. Purity of the glomerular preparation

was greater than 98% as determined by light microscopy.

3. Podocytes culture

Conditionally immortalized mouse podocytes were kindly provided by Dr. Peter Mundel (Albert Einstein College of Medicine, Bronx, NY) and were cultured as previously described³⁶. Briefly, frozen podocytes were first grown under permissive conditions at 33°C in RPMI 1640 media containing 10% fetal bovine serum, 50 U/ml γ -interferon and 100 U/ml of penicillin/streptomycin in collagen coated flasks, and the γ -interferon tapered down to 10 U/ml in successive passages. Cells were then trypsinized and subcultured without γ -interferon (non-permissive conditions) and allowed to differentiate at 37°C with media changed on alternate days. Differentiation of podocytes grown for 10 days at 37°C was confirmed by the identification of synaptopodin, a podocyte differentiation marker, by RT-PCR and Western blotting (data not shown).

In this study, siRNA for mouse HO-1 was used to inhibit HO-1 expression. The sense and antisense sequences of mouse HO-1 siRNA were as follows: sense, 5'-GGCUUUAAGCUGGUGAUGGTT-3'; and antisense, 5'-CCAUCACCAGCUUAAAGCCTT-3'. The concentrations of siRNA for this study were determined based on the preliminary experiments with three different

concentrations of 10 nM, 20 nM and 50 nM. The HO-1 siRNA were transiently transfected into differentiated podocytes with Lipofectamine 2000 (Invitrogen Co., Carlsbad, CA, USA) for 24 hours.

Transfected and nontransfected podocytes were serum-restricted for 24 hours, after which the medium was changed to RPMI medium containing normal glucose (5.6 mM glucose, NG), NG+24.4 mM mannitol (NG+M), NG+20 nM HO-1 siRNA (Ambion, Inc., Austin, Tx, USA) (NG+siRNA), high glucose (30 mM glucose, HG), or HG+20 nM HO-1 siRNA (HG+siRNA). After 24 hours, cells were harvested for either RNA or protein.

4. Total RNA isolation

Total RNA was extracted as previously described³⁷. Briefly, addition of 100 μ l of RNA STAT-60 reagent (Tel-Test, Inc., Friendswood, TX, USA) to the glomeruli was followed by glomerular lysis by freezing and thawing three times. Another 700 μ l of RNA STAT-60 reagent was added, the mixture vortexed and stored for 5 minutes at room temperature, 400 μ l of chloroform added, and the mixture shaken vigorously for 30 seconds. After 3 minutes, the mixture was centrifuged at 12,000 g for 15 minutes at 4°C and the upper aqueous phase containing the extracted RNA was transferred to a new tube. RNA was precipitated from the aqueous phase by 400 μ l isopropanol and

pelleted with centrifugation at 12,000 g for 30 minutes at 4°C. The RNA precipitate was washed with 70% ice-cold ethanol, dried using Speed Vac, and dissolved in DEPC-treated distilled water. The RNA yield and quality were assessed based on spectrophotometric measurements at the wavelength of 260 and 280 nm. Total RNA from cultured podocytes was extracted similarly.

5. Reverse transcription

First strand cDNA was made by using a Boehringer Mannheim cDNA synthesis kit (Boehringer Mannheim GmbH, Mannheim, Germany). Two µg of total RNA extracted from sieved glomeruli and cultured podocytes were reversely transcribed using 10 µM random hexanucleotide primer, 1 mM dNTP, 8 mM MgCl₂, 30 mM KCl, 50 mM Tris-HCl, pH 8.5, 0.2 mM dithiothreitol, 25 U RNase inhibitor, and 40 U AMV reverse transcriptase. The mixture was incubated at 30°C for 10 minutes and 42°C for 1 hour followed by inactivation of the enzyme at 99°C for 5 minutes.

6. Real-time PCR

The primers used for HO-1 and 18s amplifications were as follows: HO-1 sense 5'-GGTGATGCTGACAGAGGAACAC-3', antisense 5'-TAGCAGGCCTCTGACGAAGTG-3'; and 18s sense, 5'-AGTCCCTGCCCTTTGTACA

CA-3', antisense 5'-GATCCGAGGGCCTCACTAAAC-3'. Using the ABI PRISM[®] 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA), the PCR was performed with a total volume of 20 μ l in each well, containing 10 μ l of SYBR Green[®] PCR Master Mix (Applied Biosystems), 5 μ l of cDNA corresponding to 25 ng of RNA, and 5 pmol sense and antisense primers. Each sample was run in triplicate in separate tubes to permit quantification of the HO-1 gene normalized to the 18s gene. The PCR conditions were as follows: for HO-1, 38 cycles of denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, and extension at 72°C for 1 minute; and for 18s, 35 cycles of denaturation at 94.5°C for 30 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for 1 minute. An initial heating at 95°C for 9 minutes and a final extension at 72°C for 7 minutes were performed for all PCRs. After real-time PCR, the temperature was increased from 60 to 95°C at a rate of 2°C/min to construct a melting curve. A control without cDNA was run in parallel with each assay. The cDNA content of each specimen was determined using a comparative CT method with $2^{-\Delta\Delta CT}$. The results are given as relative expression normalized to the 18s gene and expressed in arbitrary units. Signals from C glomeruli and NG podocytes were assigned a relative value of 1.0. In pilot experiments, PCR products run on agarose gels revealed a single band.

7. Western blot analysis

Sieved glomeruli and podocytes harvested from plates were lysed in sodium dodecyl sulfate (SDS) sample buffer (2% sodium dodecyl sulfate, 10 mM Tris-HCl, pH6.8, 10% [vol/vol] glycerol). Lysate was centrifuged at 10,000 g for 10 minutes at 4°C and the supernatant was stored at -70°C until all rats were sacrificed. Protein concentrations were determined with a Bio-Rad kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Aliquots of 50 µg proteins were treated with Laemmli sample buffer, then heated at 100°C for 5 minutes, and electrophoresed 50 µg/lane in 8% or 12% acrylamide denaturing SDS polyacrylamide gel. Proteins were transferred to Hybond-ECL membrane (Amersham Life Science, Inc., Arlington Heights, IL, USA) using a Hoeffer semidry blotting apparatus (Hoeffer Instruments, San Francisco, CA, USA), and the membrane was then incubated in blocking buffer A (1 X PBS, 0.1% Tween-20, and 8% non-fat milk) for 1 hour at room temperature, followed by an overnight incubation at 4°C in a 1:1000 dilution of monoclonal antibody to HO-1 (EMD Biosciences, Inc., Darmstadt, Germany), polyclonal antibodies to active fragments of caspase-3 (Cell Signaling, Beverly, MA, USA), Bax, Bcl-2, or β-actin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The membrane was washed three times and then incubated with a 1:1000 dilution of horseradish peroxidase-linked goat anti-

rabbit IgG (Amersham Life Science, Inc.). The washes were repeated, and the membrane was developed with chemiluminescent agent (ECL; Amersham Life Science, Inc.). The band densities were measured using TINA image software (Raytest, Straubenhardt, Germany), and the changes in the optical densities relative to C glomeruli and NG cells were used for analysis.

8. Immunohistochemistry

Slices of kidney for immunohistochemical staining were fixed in 10% neutral buffered formalin, processed in the standard manner, and 4 μ m sections of paraffin embedded tissues were utilized. Slides were deparaffinized, hydrated in ethyl alcohol, and washed in tap water. Antigen retrieval was carried out in 10 mM sodium citrate buffer for 20 minutes using a Black and Decker vegetable steamer. For HO-1, the primary monoclonal anti-HO-1 antibody (EMD Biosciences, Inc.) was diluted in 1:200 with 2% casein in BSA and was applied for overnight incubation at room temperature. After washing, a secondary goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) was added for 20 minutes, and the slides were then washed and incubated with a tertiary rabbit-PAP complex for 20 minutes. DAB was added for 2 minutes and the slides were counterstained with hematoxylin. A semi-quantitative score for measuring the intensity of

HO-1 staining within glomeruli was determined by examining thirty glomeruli in each section and by digital image analysis (MetaMorph version 4.6r5, Universal Imaging Corp., Downingtown, PA, USA) as previously described³⁸. Briefly, the degree of staining was semi-quantitated on a scale of 0-4+ and a staining score was obtained by multiplying the intensity of staining by the percentage of glomeruli staining for that intensity; these numbers were then added for each experimental animal to give the staining score.

\sum (intensity of staining) x (% of glomeruli with that intensity) = staining score

Immunohistochemical staining for WT-1 was also performed to determine the number of podocyte as described previously³⁹. Briefly, two adjacent 3 μ m sections stained with WT-1 were observed in pairs at a magnification of x 400, and the WT-1-positive stained nuclei present in the top but not in the bottom section were counted and summed. Ten glomeruli in five rats from each group and 13 to 15 sections from the midglomerular area were examined.

9. Immunofluorescence

Slices of kidney for immunofluorescence staining were snap-frozen in optimal cutting temperature (OCT) solution and 4 μ m sections of tissues were utilized. Slides were fixed in acetone for 10 minutes at 4°C, air dried for 10

minutes at room temperature, and blocked with 10% donkey serum for 20 minutes at room temperature. For caspase-3 staining, the primary polyclonal antibody to active fragments of caspase-3 (Cell Signaling) was diluted in 1:100 with antibody diluent (DAKO, Glostrup, Denmark) and was applied for 3 hours at room temperature. After washing, Cy3 (red)-conjugated anti-rabbit IgG antibody (Research Diagnostics, Inc., Flanders, NJ, USA) was added for 60 minutes. For synaptopodin double staining, a 1:200 dilution of polyclonal anti-synaptopodin antibody (Santa Cruz Biotechnology, Inc.) was applied, followed by Cy2 (green)-conjugated anti-goat IgG antibody. A semi-quantitative score for measuring intensity of active fragments of caspase-3 was determined as aforementioned.

10. TUNEL assay and Hoechst 33342 staining

In addition to the changes in the expression of apoptosis-related molecules, apoptosis was also identified within glomeruli by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL) using commercially available kit (Chemicon International, Temecula, CA, USA) and in cultured podocytes seeded on cover slips by Hoechst 33342 (Molecular Probes, Eugene, OR, USA) staining. Apoptosis was defined as TUNEL-positive cells within glomeruli and the presence of

nuclear condensation on Hoechst staining. TUNEL-positive glomerular cells in formalin-fixed renal tissue and the percentage of podocytes with nuclear condensation were determined by examining at least 30 glomeruli and 300 cells per condition, respectively, at x 400 magnification.

11. Statistical analysis

All values are expressed as the mean \pm standard error of the mean (SEM). Statistical analysis was performed using the statistical package SPSS for Windows Ver. 11.0 (SPSS, Inc., Chicago, IL, USA). Results were analyzed using the Kruskal-Wallis nonparametric test for multiple comparisons. Significant differences by the Kruskal-Wallis test were confirmed by the Mann-Whitney U test. P values less than 0.05 were considered to be statistically significant.

III. RESULTS

1. Animal studies

A. Clinical data

Body weight and the ratio of kidney weight to body weight were significantly different between DM (275±8 g, 1.12±0.11%) and C rats (398±8 g, 0.69±0.04%) ($p<0.05$), but the administration of ZnPP had no effect on body weight and the ratio of kidney weight to body weight in C and DM rats. The mean blood glucose levels of C, C+ZnPP, DM, and DM+ZnPP were 97.2±7.7 mg/dL, 94.1±5.4 mg/dL, 497.2±14.8 mg/dL, and 488.7±17.2 mg/dL, respectively ($p<0.01$). Compared to the C group (0.32±0.04 mg/day), 24-hour urinary albumin excretion was significantly higher in the DM group (1.18±0.11 mg/day, $p<0.05$), and was further increased in DM rats by ZnPP treatment (1.59±0.19 mg/day, $p<0.05$) (Table 1).

Table 1. Animal data

	Control (N=8)	Control+ZnPP (N=8)	DM (N=8)	DM+ZnPP (N=8)
Body Wt (g)	398±8	405±7	275±8*	266±2*
Kidney Wt/Body Wt (%)	0.69±0.04	0.75±0.05	1.12±0.11*	1.20±0.09*
Blood glucose (mg/dl)	97.2±7.7	94.1±5.4	497.2±14.8 [#]	488.7±17.2 [#]
24hr UAE (mg/day)	0.32±0.04	0.29±0.08	1.18±0.11*	1.59±0.19 ^{#,§}

* $p<0.05$ vs. Control group; [#] $p<0.01$ vs. Control group; [§] $p<0.05$ vs. DM group. Wt, weight; UAE: urinary albumin excretion

B. Glomerular expression of HO-1 mRNA and protein

Glomerular HO-1 mRNA expression assessed by real-time PCR was significantly higher in DM compared to C rats ($p < 0.01$), and ZnPP treatment significantly inhibited the increase in HO-1 mRNA expression in DM rats ($p < 0.05$) (Figure 1). Similarly, there was a 2.4 fold increase in HO-1 protein expression in DM compared to C glomeruli ($p < 0.05$), and this increase was significantly ameliorated in DM rats by ZnPP treatment ($p < 0.05$) (Figure 2). On the other hand, ZnPP had no effect on glomerular HO-1 mRNA and protein expression in C rats. These results suggest that the administration of ZnPP inhibited the increase in HO-1 expression in DM glomeruli.




Figure 1. Glomerular HO-1 mRNA expression assessed by real-time PCR in C, C+ZnPP, DM, and DM+ZnPP rats. HO-1/18s mRNA ratio was 5.1-fold higher in DM compared to C glomeruli, and ZnPP treatment significantly inhibited the increase in glomerular HO-1/18s mRNA ratio in DM rats by 46.6%. * $p < 0.01$ vs. C and C+ZnPP groups; # $p < 0.05$ vs. Other groups.




Figure 2. A representative Western blot of glomerular HO-1 in C, C+ZnPP, DM, and DM+ZnPP rats (representative of four blots). HO-1 protein expression was 2.4-fold higher in DM compared to C glomeruli, and this increase was significantly ameliorated in DM rats by ZnPP treatment. * $p < 0.05$ vs. Other groups.

C. Immunohistochemical staining for glomerular HO-1

Immunohistochemical staining for glomerular HO-1 confirmed the Western blot findings. Glomerular HO-1 staining was significantly stronger in DM than in C rats, and ZnPP treatment abrogated the increase in HO-1 staining in DM glomeruli (Figure 3). The mean semi-quantitative staining score for glomerular HO-1 was significantly higher in DM (75.7 ± 9.0) compared to C rats (22.4 ± 2.4) ($p < 0.05$), and this increase was attenuated in DM glomeruli by the administration of ZnPP (37.8 ± 5.4) ($p < 0.05$).





Figure 3. Immunohistochemical staining for HO-1 in C, C+ZnPP, DM, and DM+ZnPP rats. Glomerular HO-1 staining (arrow heads) was significantly stronger in DM compared to C and C+ZnPP rats, and this increase was attenuated in DM glomeruli by the administration of ZnPP. (x 400) * $p < 0.05$ vs. Other groups.

D. Bax, Bcl-2, and active fragments of caspase-3 protein expression

Bax and active fragments of caspase-3 protein expression were significantly increased, while Bcl-2 protein expression was significantly decreased in DM compared to C glomeruli ($p < 0.05$). The administration of ZnPP significantly aggravated the increases in the ratios of Bax/Bcl-2 and active fragments of caspase-3 protein expression in DM glomeruli ($p < 0.05$) (Figure 4).




Figure 4. A representative Western blot of Bax, Bcl-2, and active fragments of caspase-3 protein expression in C, C+ZnPP, DM, and DM+ZnPP glomeruli (representative of four blots). The ratios of Bax/Bcl-2 (A) and active fragments of caspase-3 protein expression (B) were significantly increased in DM compared to C glomeruli, and the administration of ZnPP significantly aggravated these increases in DM glomeruli. * $p < 0.05$ vs. Other groups; # $p < 0.01$ vs. C and C+ZnPP groups.

E. TUNEL assay and double immunofluorescence staining

In addition to Bax, Bcl-2, and active fragments of caspase-3 protein expression, apoptosis in glomeruli was assessed by TUNEL assay. The number of glomerular apoptotic cells was significantly increased in DM compared to C and C+ZnPP rats ($p < 0.05$), and was further increased in DM rats by ZnPP treatment ($p < 0.05$) (Figure 5). To identify podocyte apoptosis in glomeruli, double immunofluorescence staining with antibodies to synaptopodin and active fragments of caspase-3 was performed. As seen in Figure 6, C and C+ZnPP rats showed minimal staining of active fragments of caspase-3 with no colocalization with synaptopodin, while the colocalization signal was increased in DM glomeruli and was highest in the glomeruli of DM+ZnPP rats.





Figure 5. Apoptosis assessed by TUNEL assay in C, C+ZnPP, DM, and DM+ZnPP rats. There was a significant increase in apoptotic cells (arrow heads) in DM compared with C and C+ZnPP glomeruli, and this increase in apoptotic cells was accentuated with ZnPP treatment. (x 400) * $p < 0.05$ vs. Other groups; # $p < 0.01$ vs. C and C+ZnPP groups.




Figure 6. Double immunofluorescence staining for active fragments of caspase-3 (red) and synaptopodin (green). Compared to C and C+ZnPP rats, the colocalization signal (yellow) was increased in DM glomeruli, and was highest in the glomeruli of DM+ZnPP rats. (x 400)

F. Podocyte numbers

Compared to C (170.0 ± 4.2) and C+ZnPP rats (168.3 ± 5.9), the number of podocyte tended to be decreased in DM rats (159.1 ± 3.7), and the reduction in podocyte numbers was aggravated in DM rats treated with ZnPP (142.9 ± 3.2) ($p < 0.05$) (Figure 7).




Figure 7. Podocyte numbers in C, C+ZnPP, DM, and DM+ZnPP rats. The number of podocyte tended to be decreased in DM rats, and the reduction in podocyte numbers was aggravated in DM rats treated with ZnPP. * $p < 0.05$ vs. Other groups.

2. Cultured podocytes studies

A. HO-1 protein expression

Western blot analysis revealed that HO-1 siRNA inhibited HO-1 protein expression in a dose-dependent manner (Figure 8). On the other hand, high glucose significantly increased HO-1 protein expression in cultured podocytes by 131% compared to NG and NG+M cells ($p < 0.05$) (Figure 9).




Figure 8. A representative Western blot of HO-1 in cultured podocytes treated with three different concentrations of HO-1 siRNA (representative of four blots). HO-1 siRNA inhibited HO-1 protein expression in a dose-dependent manner. * $p < 0.05$ vs. NG group; # $p < 0.01$ vs. NG group.




Figure 9. A representative Western blot of HO-1 in cultured podocytes exposed to NG, NG+M, and HG medium (representative of four blots). There was a significant increase in HO-1 expression in HG-stimulated podocytes compared to NG and NG+M cells. * $p < 0.05$ vs. NG and NG+M groups.

B. Bax, Bcl-2, and active fragments of caspase-3 expression

The ratios of Bax/Bcl-2 and active fragments of caspase-3 protein expression were significantly increased in HG-stimulated podocyte compared to podocytes exposed to NG and NG+M medium ($p<0.05$), and these increases were accentuated in HG cells by HO-1 siRNA ($p<0.05$). Bax/Bcl-2 protein ratios and active fragments of caspase-3 protein expression were also increased in HO-1 siRNA-treated NG cells, but did not reach statistical significance (Figure 10).




Figure 10. A representative Western blot of Bax, Bcl-2, and active fragments of caspase-3 in cultured podocytes (representative of four blots). The ratios of Bax/Bcl-2 (A) and active fragments of caspase-3 protein expression (B) were significantly increased in HG-stimulated podocyte compared to NG and NG+M groups, and these increases were accentuated in HG cells by HO-1 siRNA (20 nM). * $p < 0.05$ vs. Other groups; # $p < 0.01$ vs. NG, NG+M, and NG+siRNA groups.

C. Hoechst 33342 staining

Apoptotic cells assessed by Hoechst 33342 staining were significantly increased in HG-stimulated podocytes compared to NG cells ($p < 0.05$), and apoptosis in HG podocytes was significantly augmented by HO-1 siRNA ($p < 0.05$) (Figure 11).




Figure 11. Apoptosis assessed by Hoechst 33342 staining. There was a significant increase in apoptotic cells (arrow heads) in HG-stimulated podocytes compared to NG cells, and apoptosis in HG podocytes was significantly augmented by HO-1 siRNA. * $p < 0.05$ vs. Other groups; # $p < 0.01$ vs. NG, NG+M, and NG+siRNA groups.

IV. DISCUSSION

Previous studies have demonstrated that HO-1 plays a protective role in various kidney diseases, of which oxidative stress is implicated in the pathogenesis. However, its functional significance in terms of podocyte apoptosis in diabetic nephropathy has never been elucidated. In this study, I demonstrate for the first time that HO-1 expression is increased in experimental diabetic glomeruli and in high glucose-stimulated podocytes and that podocyte apoptosis under diabetic conditions is partly protected by this increase in HO-1 expression.

Although the term 'oxidative stress' has been of wide use, no clear definition exists yet. A number of researchers, however, see oxidative stress as a status where production of the short-lived, highly-reactive molecules such as superoxide anion, hydrogen peroxide, and peroxynitrite is increased⁴⁰. Recently, accumulating clinical and experimental evidences indicate that excessive oxidative stress contributes to the initiation and development of diabetic nephropathy. High glucose *per se*⁴¹, TGF- β 1^{42, 43}, and AII⁴⁴, major mediators involved in the development of diabetic nephropathy, are all reported to increase ROS in cultured mesangial cells. ROS is known to mediate both in vivo and in vitro activation of protein kinase C, nuclear factor

(NF)- κ B, TGF- β 1, fibronectin, and plasminogen activator inhibitor (PAI)-1 under diabetic conditions^{11, 45}. In high glucose-stimulated mesangial cells, anti-oxidant treatment normalized PKC and NF- κ B activation as well as PAI-1 expression, suggesting that ROS might mediate the high glucose-induced changes in cultured mesangial cells^{10, 42, 46}. Activation of glomerular PKC- δ and PKC- ϵ and increased glomerular TGF- β 1 and fibronectin mRNA expression in diabetic animals were also inhibited by the administration of anti-oxidant, resulting in amelioration of glomerular basement membrane thickening, mesangial expansion, and proteinuria⁴⁷.

On the other hand, the number of podocytes is decreased in the glomeruli of patients with type 1 diabetes of all ages, even in diabetes of short duration⁴⁸. Analysis of kidney biopsies from Pima Indians with type 2 diabetes demonstrated that subjects with clinical nephropathy exhibited broadening of foot processes associated with a reduced number of podocytes per glomerulus⁴⁹. Podocyte number usually reflects the balance between podocyte loss and proliferation. Therefore, a decrease in podocyte number can occur by increased loss and/or lack of proliferation. Previous studies have demonstrated that podocyte apoptosis is involved in the process of podocyte loss under diabetic conditions, and that high glucose *per se*¹², TGF- β 1⁵⁰, and high

concentrations of AII⁵¹ induce apoptosis in cultured podocytes. While AII-induced podocyte apoptosis was partly TGF- β 1-dependent, high glucose and TGF- β 1 increased ROS production and apoptosis in cultured podocytes via proapoptotic p38 mitogen-activated protein kinase (MAPK) pathway¹². Systemic inhibition of NADPH oxidase also prevented podocyte apoptosis, reduced loss of podocytes, and ameliorated urinary albumin excretion in *db/db* mice¹². Furthermore, the decrease in podocyte density in diabetic rat with early diabetic nephropathy was prevented by anti-oxidant therapy with lipoic acid¹³. Taken together, increased ROS generation may constitute a major mediator of podocyte apoptosis under diabetic conditions. In this study, I found that the expression of apoptosis-related molecules, Bax and active fragments of caspase-3, were increased in experimental diabetic glomeruli and in high glucose-stimulated podocytes, leading to a decrease in podocyte number, which was consistent with previous studies¹².

HO is a catalyzing enzyme that cleaves the heme ring, converts heme to biliverdin, and releases iron and CO¹⁴⁻¹⁶. By this process, HO regulates the cellular levels of heme, which is known to act as a pro-oxidant and to induce cell dysfunction. Therefore, when cellular heme levels are increased by denaturation or destabilization of heme protein during cell injury, HO is

supposed to be increased to remove heme and to replace it by bilirubin, a potent anti-oxidant. The cytoprotective role of HO was first suggested by Keyse et al⁵². They identified sodium arsenite-induced 32-kDa protein in cultured human skin fibroblasts as HO and showed that HO gene is also induced by UVA radiation, hydrogen peroxide, and heavy metal salts. Based on these findings, they suggested that the induction of HO may be a general response to oxidant stress and constitutes an important cellular defense mechanism against oxidative damage. After this report, numerous studies have investigated the expression and the functional role of HO, especially of HO-1, which is the largely induced isoform of HO under stressed conditions. In the kidney, HO-1 is weakly expressed in proximal and distal tubules, in Henle's loop, and in medullary collecting ducts under normal state, but its expression is increased under various conditions¹⁴. The functional role of increased HO-1 expression has been elucidated in toxic nephropathy²² and in renal ischemia-reperfusion injury^{32, 53-55}, of which oxidative stress plays a role in the pathogenesis, by inducing or inhibiting HO-1 expression. Upregulation of HO-1 reduced renal injury induced by cyclosporine²² and potassium dichromate⁵⁶, and protected tubular cell injury induced by cisplatin²¹, whereas inhibition of HO-1 expression exacerbated renal injury in maleate nephropathy³¹ and worsened cisplatin-induced cell injury⁵⁷. In addition,

induction of HO-1 by hemolysate⁵³, tin chloride⁵⁴, or cobalt⁵⁵ ameliorated ischemic acute renal injury in rats, while mild renal ischemia exerted severe renal dysfunction and increased mortality in HO-1 knockout mice compared to control mice⁵³⁻⁵⁵. Taken together, HO-1 seems to be induced to play an important cytoprotective role in oxidative stress-induced renal injury.

Based on these previous reports, HO-1 expression was surmised to be increased in diabetic nephropathy in response to oxidative stress. Recently, Hayashi et al.³⁵ and Koya et al.²⁶ demonstrated that HO-1 mRNA and protein expression were induced in diabetic glomeruli and anti-oxidant treatment nearly normalized the increase in HO-1 expression, suggesting that glomerular HO-1 expression was increased secondary to diabetes-induced oxidative stress. The former investigators also showed that the glomerular cells with increased HO-1 protein expression were mesangial cells and podocytes. However, the two aforementioned studies did not examine the biologic significance of increased glomerular HO-1 expression under diabetic conditions. The present study also demonstrated that HO-1 expression was increased not only in experimental diabetic glomeruli but also in high glucose-stimulated podocytes, which was in accordance with previous studies^{26,35}.

The cytoprotective effect of HO-1 seems to be attributed to the anti-apoptotic and anti-inflammatory effects of the HO system. Shiraishi et al.²¹ showed that renal failure and renal injury characterized by tubular apoptosis were more severe in transgenic mice deficient in HO-1 compared to wild type mice treated with cisplatin. Cisplatin-induced apoptosis in cultured proximal tubular epithelial cells was significantly attenuated by inducing HO-1 expression, whereas inhibition of HO-1 enzyme activity reversed the anti-apoptotic effect. Based on these findings, they postulated that HO-1 had a cytoprotective effect by preventing apoptosis induced by oxidative stimuli. The anti-apoptotic effect of HO-1 seems to be mediated by upregulating the expression of p21, an anti-apoptotic cell cycle protein, in renal tubular epithelial cells⁵⁸. In some cells, CO, a metabolite of the HO system, is responsible for the anti-apoptotic effect of HO-1, while augmentation of iron efflux by HO-1 contributes to its anti-apoptotic property in cultured fibroblasts⁵⁹. The present study demonstrated for the first time that apoptosis in experimental diabetic glomeruli and in high glucose-stimulated podocytes was further accentuated in HO-1-suppressed state both in vivo and in vitro, suggesting that podocyte HO-1 expression seemed to be induced to protect podocyte apoptosis under diabetic conditions. Moreover, double immunofluorescence staining with active fragments of caspase-3 and

synaptopodin in ZnPP-treated diabetic rats revealed that glomerular cells with augmented apoptosis were podocytes. Based on these findings, the further increase in albuminuria in diabetic rats treated with ZnPP may also be attributed to exacerbated apoptosis of podocytes under HO-1-inhibited state.

On the other hand, HO-1 is also known to suppress inflammation in models of tubulointerstitial disease by inhibiting the expression of monocyte chemoattractant protein-1 (MCP-1), the most important mediator of inflammatory cells infiltration⁶⁰. Ischemic insult, which exerted little effect in wild type mice, induced MCP-1 mRNA and caspase-3 expression, activated NF- κ B, and increased mortality in HO-1 knockout mice. Diabetic nephropathy is generally considered a nonimmune renal disorder, however, recent studies have suggested that an inflammatory mechanisms also contribute to the pathogenesis of diabetic nephropathy and that MCP-1 plays a critical role in the pathogenesis of diabetic nephropathy via inducing inflammatory cells infiltration^{61, 62}. In this study, I did not examine the expression of MCP-1 in podocytes under diabetic conditions and the changes in MCP-1 expression after suppressing HO-1 expression, because MCP-1 expression was not detected in podocytes and inflammatory cells infiltration was mainly demonstrated in diabetic tubulointerstitium.

To clarify the functional role of HO-1 in diabetic nephropathy, ZnPP and HO-1 siRNA were used to inhibit HO-1 in vivo and in vitro, respectively, in this study. The majority of previous in vivo studies^{27, 63, 64} used ZnPP to suppress HO-1 activity, but ZnPP were known to inhibit not only HO-1 but also HO-2 at transcription levels^{63, 65}. For this reason, the results of the in vivo study could not definitely determine whether the increase in podocyte apoptosis was due to the blockade of HO-1 and/or HO-2 activity. For the in vitro experiments, therefore, HO-1 siRNA was introduced to selectively inhibit HO-1, which led to an increase in apoptosis of podocytes under diabetic conditions, which was consistent with the animal study. On the other hand, since the consequences of HO-1 induction on podocyte apoptosis under diabetic conditions were not examined in this study, further study will be needed to elucidate whether upregulation of HO-1 by inducers such as hemin and cobalt protoporphyrin confers cytoprotection in diabetic nephropathy. However, it should be noted that it is difficult to determine the degree of HO-1 induction because overexpression of HO-1 can be deleterious in certain conditions⁶⁶.

In conclusion, HO-1 expression was increased in both experimental diabetic glomeruli and high glucose-stimulated podocytes. Moreover,

inhibition of HO-1 expression further increased albuminuria, reduced podocyte numbers in diabetic rats, and accentuated podocyte apoptosis in diabetic glomeruli and in high glucose-stimulated podocytes. Taken together, these results suggest that podocyte HO-1 expression is induced to protect podocyte against apoptosis under diabetic conditions.

V. CONCLUSION

In this study, I investigated whether HO-1 expression was increased in experimental diabetic glomeruli and in high glucose-stimulated podocytes. In addition, to elucidate the functional role of HO-1, I examined podocyte apoptosis under diabetic conditions before and after inhibition of HO-1 activity.

1. 24-hour urinary albumin excretion was significantly higher in DM (1.18 ± 0.11 mg/day, $p < 0.05$) compared to C rats (0.32 ± 0.04 mg/day), and was further increased in DM rats by ZnPP treatment (1.59 ± 0.19 mg/day, $p < 0.05$).
2. Glomerular HO-1 mRNA and protein expression were significantly higher in DM compared to C rats ($p < 0.01$), and ZnPP treatment significantly inhibited the increase in HO-1 expression in DM rats ($p < 0.05$).
3. Glomerular HO-1 staining was significantly stronger in DM relative to C and C+ZnPP rats ($p < 0.05$), and this increase was attenuated in DM glomeruli by the administration of ZnPP.
4. The ratios of Bax/Bcl-2 and active fragments of caspase-3 protein

expression were significantly increased in DM compared to C glomeruli ($p<0.05$), and the administration of ZnPP significantly accentuated these increases in DM glomeruli ($p<0.05$).

5. TUNEL positive-stained nuclei were also significantly increased in DM relative to C glomeruli ($p<0.05$), and this increase was significantly augmented in DM rats with ZnPP treatment ($p<0.05$).
6. Double IF staining with active fragments of caspase-3 and synaptopodin revealed that the colocalization signal was increased in DM glomeruli and was highest in the glomeruli of DM+ZnPP rats.
7. The number of podocyte was decreased in DM (159.1 ± 3.7) compared to C (170.0 ± 4.2) and C+ZnPP rats (168.3 ± 5.9), and the reduction in podocyte numbers was aggravated in DM rats treated with ZnPP (142.9 ± 3.2) ($p<0.05$).
8. HO-1 siRNA inhibited HO-1 protein expression in cultured podocytes in a dose-dependent manner.
9. High glucose significantly increased HO-1 protein expression in cultured podocytes by 131% compared to NG and NG+M cells ($p<0.05$).
10. The ratios of Bax/Bcl-2 and active fragments of caspase-3 protein expression were significantly increased in HG-stimulated podocytes

relative to NG and NG+M groups ($p<0.05$), and these increases were significantly accentuated in HG cells by HO-1 siRNA ($p<0.05$).

11. Apoptotic cells assessed by Hoechst 33342 staining were also significantly increased in HG-stimulated podocytes compared to NG cells, and apoptosis in HG podocytes was significantly augmented by HO-1 siRNA ($p<0.05$).

In summary, HO-1 expression was increased in both experimental diabetic glomeruli and high glucose-stimulated podocytes. Moreover, inhibition of HO-1 expression further increased albuminuria, reduced podocyte numbers in diabetic rats, and accentuated podocyte apoptosis in diabetic glomeruli and in high glucose-stimulated podocytes. Taken together, these results suggest that podocyte HO-1 expression is induced to protect podocyte against apoptosis under diabetic conditions.

REFERENCES

1. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. *J Am Soc Nephrol.* 2007;18:2644-8.
2. Menne J, Park JK, Boehne M, Elger M, Lindschau C, Kirsch T, et al. Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. *Diabetes.* 2004;53:2101-9.
3. Reddy GR, Kotlyarevska K, Ransom RF, Menon RK. The podocyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy? *Curr Opin Nephrol Hypertens.* 2008;17:32-6.
4. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. *Diabetes.* 2005;54:1626-34.
5. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. *N Engl J Med.* 2006; 354:1387-401.
6. Li JJ, Kwak SJ, Jung DS, Kim JJ, Yoo TH, Ryu DR, et al. Podocyte biology in diabetic nephropathy. *Kidney Int Suppl.* 2007;72:S36-42.
7. Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P. Is podocyte injury relevant in diabetic nephropathy? Studies in patients

- with type 2 diabetes. *Diabetes*. 2003;52:1031-5.
8. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. *Kidney Int*. 2006;69:2131-47.
 9. Verzola D, Gandolfo MT, Ferrario F, Rastaldi MP, Villaggio B, Gianiorio F, et al. Apoptosis in the kidneys of patients with type II diabetic nephropathy. *Kidney Int*. 2007;72:1262-72.
 10. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature*. 2000;404:787-90.
 11. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. *J Am Soc Nephrol*. 2003;14(8 Suppl 3):S241-5.
 12. Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. *Diabetes*. 2006;55:225-33.
 13. Siu B, Saha J, Smoyer WE, Sullivan KA, Brosius FC, 3rd. Reduction in podocyte density as a pathologic feature in early diabetic nephropathy in rodents: prevention by lipoic acid treatment. *BMC Nephrol*. 2006;7:6.
 14. Nath KA. Heme oxygenase-1: a provenance for cytoprotective pathways in the kidney and other tissues. *Kidney Int*. 2006;70:432-43.

15. Abraham NG, Kappas A. Heme oxygenase and the cardiovascular-renal system. *Free Radic Biol Med.* 2005;39:1-25.
16. Maines MD. The heme oxygenase system: update 2005. *Antioxid Redox Signal.* 2005;7:1761-6.
17. Kirkby KA, Adin CA. Products of heme oxygenase and their potential therapeutic applications. *Am J Physiol Renal Physiol.* 2006;290:F563-71.
18. Hayashi S, Omata Y, Sakamoto H, Higashimoto Y, Hara T, Sagara Y, et al. Characterization of rat heme oxygenase-3 gene. Implication of processed pseudogenes derived from heme oxygenase-2 gene. *Gene.* 2004;336:241-50.
19. Quan S, Yang L, Shnouda S, Schwartzman ML, Nasjletti A, Goodman AI, et al. Expression of human heme oxygenase-1 in the thick ascending limb attenuates angiotensin II-mediated increase in oxidative injury. *Kidney Int.* 2004;65:1628-39.
20. Yachie A, Niida Y, Wada T, Igarashi N, Kaneda H, Toma T, et al. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. *J Clin Invest.* 1999;103:129-35.
21. Shiraishi F, Curtis LM, Truong L, Poss K, Visner GA, Madsen K, et al. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. *Am J Physiol Renal Physiol.*

- 2000;278:F726-36.
22. Rezzani R, Rodella L, Buffoli B, Goodman AA, Abraham NG, Lianos EA, et al. Change in renal heme oxygenase expression in cyclosporine A-induced injury. *J Histochem Cytochem.* 2005;53:105-12.
 23. Goncalves GM, Cenedeze MA, Feitoza CQ, Wang PM, Bertocchi AP, Damiao MJ, et al. The role of heme oxygenase 1 in rapamycin-induced renal dysfunction after ischemia and reperfusion injury. *Kidney Int.* 2006;70:1742-9.
 24. Goodman AI, Olszanecki R, Yang LM, Quan S, Li M, Omura S, et al. Heme oxygenase-1 protects against radiocontrast-induced acute kidney injury by regulating anti-apoptotic proteins. *Kidney Int.* 2007;72:945-53.
 25. Avihingsanon Y, Ma N, Csizmadia E, Wang C, Pavlakis M, Giraldo M, et al. Expression of protective genes in human renal allografts: a regulatory response to injury associated with graft rejection. *Transplantation.* 2002;73:1079-85.
 26. Koya D, Hayashi K, Kitada M, Kashiwagi A, Kikkawa R, Haneda M. Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. *J Am Soc Nephrol.* 2003;14(8 Suppl 3):S250-3.
 27. Aizawa T, Ishizaka N, Taguchi J, Nagai R, Mori I, Tang SS, et al. Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced

- hypertensive rats : possible role in renoprotection. *Hypertension*. 2000; 35:800-6.
28. Yang Y, Ohta K, Shimizu M, Morimoto K, Goto C, Nakai A, et al. Selective protection of renal tubular epithelial cells by heme oxygenase (HO)-1 during stress-induced injury. *Kidney Int*. 2003;64:1302-9.
29. Tetsuka T, Daphna-Iken D, Srivastava SK, Morrison AR. Regulation of heme oxygenase mRNA in mesangial cells: prostaglandin E2 negatively modulates interleukin-1-induced heme oxygenase-1 mRNA. *Biochem Biophys Res Commun*. 1995;212:617-23.
30. Hill-Kapturczak N, Truong L, Thamilselvan V, Visner GA, Nick HS, Agarwal A. Smad7-dependent regulation of heme oxygenase-1 by transforming growth factor-beta in human renal epithelial cells. *J Biol Chem*. 2000;275:40904-9.
31. Pedraza-Chaverri J, Murali NS, Croatt AJ, Alam J, Grande JP, Nath KA. Proteinuria as a determinant of renal expression of heme oxygenase-1: studies in models of glomerular and tubular proteinuria in the rat. *Am J Physiol Renal Physiol*. 2006;290:F196-204.
32. Shimizu H, Takahashi T, Suzuki T, Yamasaki A, Fujiwara T, Odaka Y, et al. Protective effect of heme oxygenase induction in ischemic acute renal failure. *Crit Care Med*. 2000;28:809-17.

33. Nakamura T, Ushiyama C, Suzuki S, Shimada N, Ohmuro H, Ebihara I, et al. Effects of taurine and vitamin E on microalbuminuria, plasma metalloproteinase-9, and serum type IV collagen concentrations in patients with diabetic nephropathy. *Nephron*. 1999;83:361-2.
34. Melhem MF, Craven PA, Derubertis FR. Effects of dietary supplementation of alpha-lipoic acid on early glomerular injury in diabetes mellitus. *J Am Soc Nephrol*. 2001;12:124-33.
35. Hayashi K, Haneda M, Koya D, Maeda S, Isshiki K, Kikkawa R. Enhancement of glomerular heme oxygenase-1 expression in diabetic rats. *Diabetes Res Clin Pract*. 2001;52:85-96.
36. Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson GR, Kriz W, et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. *Exp Cell Res*. 1997;236:248-58.
37. Kang SW, Adler SG, Lapage J, Natarajan R. p38 MAPK and MAPK kinase 3/6 mRNA and activities are increased in early diabetic glomeruli. *Kidney Int*. 2001;60:543-52.
38. Doublier S, Ruotsalainen V, Salvidio G, Lupia E, Biancone L, Conaldi PG, et al. Nephric redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome.

- Am J Pathol. 2001;158:1723-31.
39. Sanden SK, Wiggins JE, Goyal M, Riggs LK, Wiggins RC. Evaluation of a thick and thin section method for estimation of podocyte number, glomerular volume, and glomerular volume per podocyte in rat kidney with Wilms' tumor-1 protein used as a podocyte nuclear marker. *J Am Soc Nephrol.* 2003;14:2484-93.
 40. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? *Hypertension.* 2004;44:248-52.
 41. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB. Role of high glucose-induced nuclear factor-kappa B activation in monocyte chemoattractant protein-1 expression by mesangial cells. *J Am Soc Nephrol.* 2002; 13:894-902.
 42. Lal MA, Brismar H, Eklof AC, Aperia A. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. *Kidney Int.* 2002;61:2006-14.
 43. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. *J Clin Invest.* 1994;93:536-42.

44. Jaimes EA, Galceran JM, Raji L. Angiotensin II induces superoxide anion production by mesangial cells. *Kidney Int.* 1998;54:775-84.
45. Lee HB, Seo JY, Yu MR, Uh ST, Ha H. Radical approach to diabetic nephropathy. *Kidney Int Suppl.* 2007;106:S67-70.
46. Lee EA, Seo JY, Jiang Z, Yu MR, Kwon MK, Ha H, et al. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. *Kidney Int.* 2005;67:1762-71.
47. Ha H, Yu MR, Choi YJ, Lee HB. Activation of protein kinase c-delta and c-epsilon by oxidative stress in early diabetic rat kidney. *Am J Kidney Dis.* 2001;38(4 Suppl 1):S204-7.
48. Steffes MW, Schmidt D, McCreery R, Basgen JM. Glomerular cell number in normal subjects and in type 1 diabetic patients. *Kidney Int.* 2001;59:2104-13.
49. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, et al. Podocyte loss and progressive glomerular injury in type II diabetes. *J Clin Invest.* 1997;99:342-8.
50. Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, et al. Apoptosis in podocytes induced by TGF-beta and Smad7. *J Clin Invest.* 2001;108:807-16.

51. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. *Kidney Int.* 2004;65:30-9.
52. Keyse SM, Tyrrell RM. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. *Proc Natl Acad Sci USA.* 1989;86:99-103.
53. Yoneya R, Nagashima Y, Sakaki K, Hagiwara K, Teraoka H, Ozasa H, et al. Hemolysate pretreatment ameliorates ischemic acute renal injury in rats. *Nephron.* 2002;92:407-13.
54. Toda N, Takahashi T, Mizobuchi S, Fujii H, Nakahira K, Takahashi S, et al. Tin chloride pretreatment prevents renal injury in rats with ischemic acute renal failure. *Crit Care Med.* 2002;30:1512-22.
55. Matsumoto M, Makino Y, Tanaka T, Tanaka H, Ishizaka N, Noiri E, et al. Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. *J Am Soc Nephrol.* 2003;14:1825-32.
56. Barrera D, Maldonado PD, Medina-Campos ON, Hernandez-Pando R, Ibarra-Rubio ME, Pedraza-Chaverri J. HO-1 induction attenuates renal damage and oxidative stress induced by K₂Cr₂O₇. *Free Radic Biol Med.* 2003;34:1390-8.

57. Schaaf GJ, Maas RF, de Groene EM, Fink-Gremmels J. Management of oxidative stress by heme oxygenase-1 in cisplatin-induced toxicity in renal tubular cells. *Free Radic Res.* 2002;36:835-43.
58. Inguaggiato P, Gonzalez-Michaca L, Croatt AJ, Haggard JJ, Alam J, Nath KA. Cellular overexpression of heme oxygenase-1 up-regulates p21 and confers resistance to apoptosis. *Kidney Int.* 2001;60:2181-91.
59. Brouard S, Otterbein LE, Anrather J, Tobiasch E, Bach FH, Choi AM, et al. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. *J Exp Med.* 2000;192:1015-26.
60. Nath KA, Vercellotti GM, Grande JP, Miyoshi H, Paya CV, Manivel JC, et al. Heme protein-induced chronic renal inflammation: suppressive effect of induced heme oxygenase-1. *Kidney Int.* 2001;59:106-17.
61. Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. *Am J Physiol Renal Physiol.* 2008;294:F697-701.
62. Fornoni A, Ijaz A, Tejada T, Lenz O. Role of inflammation in diabetic nephropathy. *Curr Diabetes Rev.* 2008;4:10-7.
63. Tullius SG, Nieminen-Kelha M, Buelow R, Reutzel-Selke A, Martins PN, Pratschke J, et al. Inhibition of ischemia/reperfusion injury and chronic graft deterioration by a single-donor treatment with cobalt-

- protoporphyrin for the induction of heme oxygenase-1. Transplantation. 2002;74:591-8.
64. Kim JH, Yang JI, Jung MH, Hwa JS, Kang KR, Park DJ, et al. Heme oxygenase-1 protects rat kidney from ureteral obstruction via an antiapoptotic pathway. *J Am Soc Nephrol*. 2006;17:1373-81.
65. Kanakiriya SK, Croatt AJ, Haggard JJ, Ingelfinger JR, Tang SS, Alam J, et al. Heme: a novel inducer of MCP-1 through HO-dependent and HO-independent mechanisms. *Am J Physiol Renal Physiol*. 2003;84:F546-54.
66. Nath KA. The functional significance of induction of heme oxygenase by oxidant stress. *J Lab Clin Med*. 1994;123:461-3.

ABSTRACT (in Korean)

당뇨병성 신병증에서 heme oxygenase-1이 죽세포 사멸에 미치는 영향

<지도교수 강 신 욱>
연세대학교 대학원 의학과
이 상 철

서론: 당뇨병성 신병증은 국내외적으로 말기 신부전증의 가장 흔한 원인 질환으로, 초기에는 단백뇨가 대표적인 임상적 특징이다. 최근의 보고들에 의하면 단백뇨의 발생에 사구체 여과 장벽을 구성하는 세포의 하나인 죽세포가 중요한 역할을 하는 것으로 알려져 있다. 당뇨병성 신병증에서 죽세포의 수 및 밀도가 감소되어 있으며 이는 사구체 여과장벽의 손상을 일으켜 결국 사구체 경화증을 초래하는 요인이 되는데, 이 과정에 당뇨 조건 하에서 생성이 증가된 ROS가 관여하는 것으로 알려져 있다. Heme oxygenase-1 (HO-1)은 미소체 효소로서 산화성 스트레스에 의한 각종 조직 손상에서 발현이 증가되며, 항산화 효과, 항염증 작용, 그리고 항세포사멸 효과가 있는 것으로 보고되고 있다. 당뇨병성

신병증에서도 HO-1의 발현 증가가 보고된 바는 있으나, 그 기능적 역할에 대한 연구는 전무한 실정이다. 이에 본 연구자는 당뇨병성 신병증에서 HO-1의 발현 증가 여부를 확인하고, 당뇨병성 신병증에서 발현이 증가되는 HO-1의 기능적 의미를 알아보기 위하여 생체 내외의 실험을 통하여 HO-1 발현 억제 전후에 족세포 사멸의 변화를 알아보고자 하였다.

방법: 32마리의 Sprague-Dawley 백서를 대상으로 대조군 (16마리)과 복강 내로 streptozotocin을 투여한 당뇨군 (16마리)으로 나누었으며 각 군에서 8마리에는 HO-1의 억제제인 Zinc protoporphyrin (ZnPP, 50 $\mu\text{mol/kg/day}$)를 6주간 복강 내로 투여하였다. 또한, 불멸 생쥐 족세포 (immortalized mouse podocytes)를 정상 포도당군 (5.6 mM), 정상 포도당+만니톨군 (24.4 mM 만니톨), 정상 포도당+HO-1 siRNA 처리군, 고평도당군 (30 mM), 그리고 고평도당+HO-1 siRNA 처리군으로 나누어 배양하였다. 실험 동물로부터 분리한 사구체와 배양 족세포에서 HO-1 mRNA와 단백 발현은 각각 real-time PCR과 Western blot을 이용하여 분석하였으며, 신장 조직 내 HO-1의 단백 발현은 면역조직화학 염색을 시행하여 확인하였다. 세포사멸은 Bax, Bcl-2, 그리고 active fragments of caspase-3에 대한 Western blot을 이용하여 분석하였으며, 신장 조직을 이용한 TUNEL 염색과 배양 세포를 이용한 Hoechst 33342 염색으로도 확인하였다.

결과: 24시간 뇨알부민 배설량은 대조군 (0.32 ± 0.04 mg/day)에 비하여 당뇨군 (1.18 ± 0.11 mg/day)에서 의미있게 많았으며 ($p < 0.05$), ZnPP 투여 당뇨군에서의 뇨알부민 배설량이 유의하게 더 증가하였다 (1.59 ± 0.19 mg/day) ($p < 0.05$). 사구체 내 HO-1의 mRNA 발현은 대조군에 비하여 당뇨군에서 5.1배 증가되었으며 ($p < 0.01$), ZnPP 투여로 당뇨군에서 발현 증가가 46.6% 억제되었다 ($p < 0.05$). 사구체 내 HO-1의 단백 발현도 mRNA 발현 양상과 유사하였다. 세포 실험상 고평도당으로 자극한 족세포에서 HO-1의 단백 발현은 정상 포도당군에 비하여 2.3배 증가되었으며 ($p < 0.05$), HO-1 siRNA는 HO-1의 단백 발현을 농도 의존적으로 억제시켰다. 세포사멸의 지표인 Bax/Bcl-2 단백 발현의 비와 active fragments of caspase-3의 단백 발현은 당뇨 사구체와 고평도당으로 자극한 족세포에서 의미있게 높았으며 ($p < 0.05$), ZnPP 투여 및 HO-1 siRNA 처치로 의의있게 더 증가되었다 ($p < 0.01$). 사구체 내 TUNEL-양성 세포 수는 대조군 (0.4 ± 0.1)에 비하여 당뇨군 (1.3 ± 0.2)에서 유의하게 많았으며 ($p < 0.05$), ZnPP 투여 당뇨군 (2.2 ± 0.3)에서 의미있게 더 증가되었다 ($p < 0.05$). WT-1에 대한 면역조직화학 염색을 이용하여 측정된 족세포 수는 대조군 (170.0 ± 4.2)에 비하여 당뇨군 (159.1 ± 3.7)에서 적었으며, ZnPP를 투여한 당뇨군 (142.9 ± 3.2)에서 의의있게 더 감소되었다 ($p < 0.05$). Active fragments of caspase-3와 synaptopodin에 대한 이중

면역형광염색을 시행한 결과, 세포사멸이 동반된 세포가 주로 죽세포임을 알 수 있었다. 배양 죽세포에서 Hoechst 33342 염색을 이용하여 측정한 세포사멸이 동반된 죽세포 수도 정상 포도당군 ($3.7\pm 0.1\%$)에 비하여 고평도당군 ($11.1\pm 0.2\%$)에서 유의하게 많았으며 ($p<0.05$), HO-1 siRNA 처리군 ($17.2\pm 0.2\%$)에서 의미있게 더 증가되었다 ($p<0.05$).

결론: 당뇨병성 신병증의 동물 모델과 고평도당으로 자극한 죽세포에서 HO-1의 발현은 의의있게 증가되었으며, HO-1의 발현 증가를 억제시킬 경우 죽세포의 세포사멸이 유의하게 더 증가되었다. 이상의 결과들을 종합해 볼 때, 당뇨 조건 하에서 죽세포 내 HO-1의 발현 증가는 세포사멸에 대한 보호 역할을 할 것으로 생각된다.

핵심 되는 말: heme oxygenase-1, 당뇨병성 신병증, 죽세포, 고평도당, 세포사멸